Aleix Prat

Aleix Prat

UNVERIFIED PROFILE

Are you Aleix Prat?   Register this Author

Register author
Aleix Prat

Aleix Prat

Publications by authors named "Aleix Prat"

Are you Aleix Prat?   Register this Author

100Publications

3910Reads

10Profile Views

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

Eur J Cancer 2019 Oct 4;120:54-64. Epub 2019 Sep 4.

GEICAM (Grupo GEICAM de Investigación en Cáncer de Mama), Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain; IMIM Hospital del Mar Medical Research Institute; Barcelona, Spain; Medical Oncology Department Hospital del Mar, Barcelona, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.07.003DOI Listing
October 2019

Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients.

Transl Res 2019 06 7;208:73-84. Epub 2019 Feb 7.

Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centre de Recerca Biomèdica CELLEX, Universitat de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2019.02.003DOI Listing
June 2019

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.

J Immunother Cancer 2019 Mar 29;7(1):90. Epub 2019 Mar 29.

Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0548-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439986PMC
March 2019

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.

Cancer Treat Rev 2018 Jun 7;67:63-70. Epub 2018 May 7.

Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain; SOLTI Breast Cancer Cooperative Group, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.015DOI Listing
June 2018

Molecular Tumor Boards.

Breast Care (Basel) 2018 Apr 23;13(2):141-143. Epub 2018 Apr 23.

Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981585PMC
April 2018

Coamplification of protects -amplified breast cancers from targeted therapy.

Proc Natl Acad Sci U S A 2018 03 23;115(11):E2594-E2603. Epub 2018 Feb 23.

Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1717820115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856537PMC
March 2018

Predictive model of complexity in early palliative care: a cohort of advanced cancer patients (PALCOM study).

Support Care Cancer 2018 01 6;26(1):241-249. Epub 2017 Aug 6.

Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-017-3840-3DOI Listing
January 2018

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.

Cell Rep 2017 Nov;21(8):2183-2197

Glioma and Neural Stem Cell Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors Team, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.10.083DOI Listing
November 2017

Intrinsic molecular subtypes of HER2+ breast cancer.

Oncotarget 2017 Sep 4;8(43):73362-73363. Epub 2017 Sep 4.

Aleix Prat: Department of Medical Oncology, Hospital Clínic de Barcelona, Spain and Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650264PMC
September 2017

Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].

Eur Urol 2017 08 1;72(2):e49. Epub 2017 Mar 1.

Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.02.027DOI Listing
August 2017

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Breast 2017 Aug 4;34 Suppl 1:S19-S26. Epub 2017 Jul 4.

Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050048PMC
August 2017

Pertuzumab Use in the Adjuvant Setting: Why Not?

Authors:
Aleix Prat

J Clin Oncol 2017 04 17;35(10):1138. Epub 2017 Jan 17.

Aleix Prat, Hospital Clinic of Barcelona, and August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.6212DOI Listing
April 2017

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Lancet Oncol 2017 04 24;18(4):545-554. Epub 2017 Feb 24.

Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30021-9DOI Listing
April 2017

Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.

Future Oncol 2016 Dec 1;12(23):2683-2688. Epub 2016 Sep 1.

Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0037DOI Listing
December 2016

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.

Eur Urol 2016 11 2;70(5):709-713. Epub 2016 Mar 2.

Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.02.034DOI Listing
November 2016

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Oncotarget 2016 10;7(42):67956-67965

Breast Surgical Unit, Breast Cancer Center, Hospital Universitario Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531PMC
October 2016

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

Immunotherapy 2016 06 26;8(6):687-92. Epub 2016 Apr 26.

Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2015-0025DOI Listing
June 2016

Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.

Curr Med Res Opin 2016 05 12;32(5):835-9. Epub 2016 Feb 12.

a Lille University , Centre Oscar Lambret, Breast Cancer Department , Lille , France ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2016.1146664DOI Listing
May 2016

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis.

ESMO Open 2016 8;1(1):e000032. Epub 2016 Feb 8.

Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2015-000032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070207PMC
February 2016

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.

J Natl Cancer Inst 2015 Dec 15;107(12):djv256. Epub 2015 Sep 15.

Oncology Program (MP, AAE, AB, MT, MG, XGA, MM, JU, SG, RRG) and Biostatistics and Bioinformatics Unit (EP), Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain; Cancer Research Program (FR, AR, JA) and Microarray Analysis Service (LN), IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Pathology Department, IIS-Fundación Jimenez Diaz, Madrid, Spain (FR); Medical Oncology Service, Hospital del Mar, Barcelona, Spain (AR, JA); Department of Oncology and Hematology, Hospital Clínico Universitario, Valencia, Spain (AL); Valencia Central University, Spain (AL); Inbiomotion, Barcelona, Spain (JJM); Sheffield Cancer Research Centre, Sheffield, UK (RC); Universitat Pompeu Fabra, Barcelona, Spain (JA); Translational Genomics, Vall d'Hebron Insitute of Oncology, Barcelona, Spain (AP); Department of Epidemiology, Harvard School of Public Health, Boston, MA (XGA); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (RRG).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/12/djv256.full.pd
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv25
Publisher Site
http://dx.doi.org/10.1093/jnci/djv256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681582PMC
December 2015

Clinical implications of the intrinsic molecular subtypes of breast cancer.

Breast 2015 Nov 5;24 Suppl 2:S26-35. Epub 2015 Aug 5.

Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.008DOI Listing
November 2015

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast.

Mol Oncol 2015 Jun 31;9(6):1081-90. Epub 2015 Jan 31.

Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain; Breast Cancer Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528764PMC
June 2015

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist 2015 May 23;20(5):474-82. Epub 2015 Apr 23.

Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; GEICAM, Madrid, Spain; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; Department of Medicine, Washington University, St. Louis, Missouri, USA; Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425383PMC
May 2015

Response.

J Natl Cancer Inst 2015 Apr 24;107(4). Epub 2015 Feb 24.

Division of Cancer Epidemiology and Genetics/Biostatistics Branch (WFA, PSR) and Division of Cancer Prevention (MES), Department of Health and Human Services/National Institutes of Health/National Cancer Institute, Bethesda, MD; Translational Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (AP); Department of Genetics and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC (CMP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351399PMC
April 2015

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015

Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.

Cancer Res 2014 Dec 22;74(24):7406-17. Epub 2014 Oct 22.

Deparment of Pathology, Case Comprehensive Cancer Center, and National Center for Regenerative Medicine, Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-1188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310213PMC
December 2014

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

J Natl Cancer Inst 2014 Nov 24;106(11). Epub 2014 Sep 24.

*Authors contributed equally to this work.Affiliations of authors: Preclinical Research (JLPP, BM, ME, RV, MZF, KP, VS, AP, JA) and Clinical Research Programs (PN, JC, ITR), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain (VP); Human Oncology and Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center, New York, NY (MS, JB); Instituto de Biología Molecular y Celular del Cáncer, Campus Miguel de Unamuno, Salamanca, Spain (AP); Lineberger Comprehensive Cancer Center, Chapel Hill, NC (CMP); Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain (JA); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (JA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271027PMC
November 2014

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

Oncologist 2014 Oct 20;19(10):1076-83. Epub 2014 Aug 20.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200998PMC
October 2014

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.

Breast Cancer Res Treat 2014 Aug 22;147(1):185-91. Epub 2014 Jul 22.

Translational Genomics Group, Vall d´Hebron Institute of Oncology (VHIO), Pg Vall d´Hebron, 119-129, 08035, Barcelona, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3056-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131128PMC
August 2014

How many etiological subtypes of breast cancer: two, three, four, or more?

J Natl Cancer Inst 2014 Aug 12;106(8). Epub 2014 Aug 12.

Division of Cancer Epidemiology and Genetics Biostatistics Branch (WFA, PSR), and Division of Cancer Prevention (MES), National Cancer Institute, National Institutes of Health, Bethesda, MD; Translational Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (AP); Department of Genetics and Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC (CMP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148600PMC
August 2014

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.

J Natl Cancer Inst 2014 Aug 19;106(8). Epub 2014 Aug 19.

: Breast Cancer Unit (AP, BA, MV, JC), Department of Medical Oncology (AP, BA, MV, JC, JT), and Translational Genomics Group (AP, MV), Vall d'Hebron Institute of Oncology Barcelona, Spain; Lineberger Comprehensive Cancer Center (LAC, JSP, CMP), Department of Genetics (CMP), and Department of Pathology and Laboratory Medicine (CMP), University of North Carolina, Chapel Hill, NC; Memorial Sloan-Kettering Cancer Center, New York (JB).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151853PMC
August 2014

Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation.

Stem Cell Reports 2014 May 24;2(5):633-47. Epub 2014 Apr 24.

Department of Developmental, Molecular and Chemical Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA ; Molecular Oncology Research Institute, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stemcr.2014.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050485PMC
May 2014

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.

BMC Cancer 2014 Apr 30;14:302. Epub 2014 Apr 30.

Translational Cancer Research Unit, Albacete University Hospital, 02006 Albacete, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021223PMC
April 2014

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment.

Cell Rep 2014 Mar 6;6(6):1059-1072. Epub 2014 Mar 6.

Department of Developmental, Chemical, and Molecular Biology, Tufts University, 145 Harrison Avenue, Boston, MA 02111, USA; Molecular Oncology Research Institute, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.02.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011189PMC
March 2014

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Mol Oncol 2014 Feb 13;8(1):20-6. Epub 2013 Sep 13.

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2013.08.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528507PMC
February 2014

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.

Clin Exp Metastasis 2014 Jan 22;31(1):33-45. Epub 2013 Aug 22.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box 7295, 450 West Drive, Chapel Hill, NC, 27599, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-013-9607-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892109PMC
January 2014

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Clin Cancer Res 2014 Jan;20(2):511-21

Authors' Affiliations: Translational Genomics Group, Vall d'Hebron Institute of Oncology; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona; Hospital Clinico Universitario, Valencia, Spain; Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy; Roche, Pharma Research and Early Development, Penzberg; Frauenklinik vom Roten Kreuz, Munich, Germany; University of North Carolina, Chapel Hill, North Carolina; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; NN Blokhin Russian Cancer Centre; Central Clinical Hospital named after N A Semashko, Moscow, Russia; and Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0239DOI Listing
January 2014

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.

Clin Cancer Res 2013 Dec 29;19(24):6787-801. Epub 2013 Oct 29.

Authors' Affiliations: Translational Program, Stem Cells and Cancer Laboratory; Molecular Oncology Group; Genomics Cancer Group; and Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO); Parc de Recerca Biomèdica de Barcelona (PRBB), Centre d'Imatge Molecular (CRC) Corporació Sanitària; Departments of Pathology, Medical Oncology, and HBP Surgery and Transplantation, Vall d'Hebron University Hospital, Universidad Autónoma de Barcelona; and General Surgery Service, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1740DOI Listing
December 2013

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.

Sci Rep 2013 Dec 18;3:3544. Epub 2013 Dec 18.

1] Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain [2] Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep03544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506566PMC
December 2013

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Breast Cancer Res Treat 2013 Nov 27;142(2):237-55. Epub 2013 Oct 27.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB7295, Chapel Hill, NC, 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2743-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832776PMC
November 2013

Predicting drug responsiveness in human cancers using genetically engineered mice.

Clin Cancer Res 2013 Sep 18;19(17):4889-99. Epub 2013 Jun 18.

Lineberger Comprehensive Cancer Center, Department of Genetics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778918PMC
September 2013

SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.

Mol Cell Biol 2013 Aug 28;33(15):3011-25. Epub 2013 May 28.

Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.01443-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719671PMC
August 2013

Reply to Y.Yamamoto et al.

J Clin Oncol 2013 Jul;31(19):2517-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.9061DOI Listing
July 2013

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

J Clin Invest 2012 Apr 26;122(4):1541-52. Epub 2012 Mar 26.

Section of Breast Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110-1093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI58765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314455PMC
April 2012

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.

Proc Natl Acad Sci U S A 2012 Jan 16;109(1):221-6. Epub 2011 Dec 16.

Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1115802109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252958PMC
January 2012

Practical implications of gene-expression-based assays for breast oncologists.

Nat Rev Clin Oncol 2011 Dec 6;9(1):48-57. Epub 2011 Dec 6.

Department of Genetics and Pathology, Lineberger Comprehensive Cancer Center, University of North Carolina, 450 West Drive, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703639PMC
December 2011